GSK Sells Rights to Orphan Drug for Liver Illness

GSK said it would sell rights to linerixibat, an experimental treatment for itching caused by a liver disease, to Italian pharmaceutical company Alfasigma as part of a licensing agreement valued at up to $690 million.

- BY ADRIÀ CALATAYUD

The U.K. pharmaceutical company said it would receive $300 million upfront and be eligible to receive another $100 million upon approval for the drug in the U.S. and a further $290 million subject to achieving additional regulatory and sales-based